We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA Kit

By LabMedica International staff writers
Posted on 25 Jun 2020
Erba Mannheim (London, England) has launched the ErbaLisa COVID-19 IgM ELISA kit for the detection of IgM antibodies to SARS-CoV-2 in response to the ongoing COVID-19 pandemic.

The ready-to-use ELISA kits allows for the qualitative and semi-quantitative detection of IgG/M antibodies to SARS-CoV-2 in human serum. More...
Since IgM antibodies are produced first and detectable during disease onset, using the new assay in combination with Erba's existing ErbaLisa COVID-19 IgG ELISA can detect both early and late phases of the immune response.

Erba's solid phase assays use proven technology, and total incubation time is 50 minutes at room temperature with a simple one step serum dilution. ErbaLisa COVID-19 assays are built for superior performance and reliable interpretation of results. With full CE certification, the reliable and automation-friendly COVID-19 ELISA kits are now available through Erba's global distribution network, including in the US.

"We are working tirelessly to offer more options to clinicians and laboratories with which to gain an advantage in responding to this unprecedented global health crisis," said Nikhil Vazirani, MD of Erba Mannheim.



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Thyroid Test
Anti-Thyroid EIA Test
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new CRISPR-based technique enables simultaneous detection of multiple pathogens in a single test (photo courtesy of Shutterstock)

CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously

Respiratory virus co-circulation complicates differential diagnosis, as overlapping symptoms can obscure etiology. Multiplex testing typically depends on multiple enzymes or fluorophores and multistep... Read more

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.